Brief Title
Investigation of the Cylex® ImmuKnow® Assay
Official Title
Investigation of the Cylex® ImmuKnow® Assay
Brief Summary
Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.
Study Type
Observational
Condition
Leukemia
Study Arms / Comparison Groups
observational
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
45
Start Date
November 2007
Completion Date
December 2012
Primary Completion Date
February 2010
Eligibility Criteria
Inclusion Criteria: Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible: 1. Acute leukemia 2. Non-Hodgkin's Lymphoma 3. Chronic lymphocytic leukemia 4. Hodgkin's disease 5. Multiple myeloma 6. Myelodysplastic Syndromes 7. Myeloproliferative Disorders 8. Aplastic Anemia 9. Chronic myelogenous leukemia
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Sherif Farag, MD, PhD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00569842
Organization ID
0710-11/ IUCRO-0207
Responsible Party
Sponsor
Study Sponsor
Indiana University School of Medicine
Study Sponsor
Sherif Farag, MD, PhD, Principal Investigator, Indiana University School of Medicine
Verification Date
September 2014